湖北知化医药

湖北知化医药科技有限公司 (Hubei Zhihua Pharmaceutical Technology Co., Ltd.) is a pharmaceutical company based in Jingzhou, Hubei Province, China. The company operates primarily under the Marketing Authorization Holder (MAH) model, focusing on the development and commercialization of generic chemical drugs and medical devices. Its pharmaceutical pipeline includes Methotrexate Injection, an anti-tumor small molecule targeting dihydrofolate reductase (DHFR) that is manufactured through an outsourcing agreement with Shanxi Pude Pharmaceutical. Additionally, the company is developing Tauroursodeoxycholic acid capsules, which entered bioequivalence clinical trials in 2025. Hubei Zhihua also expands into medical devices, having received approval for its nerve monitoring endotracheal tube in late 2025.